Caring Brands, Inc. (NASDAQ:CABR) Sees Significant Increase in Short Interest

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totaling 63,992 shares, an increase of 207.7% from the May 31st total of 20,796 shares. Approximately 0.8% of the shares of the stock are short sold. Based on an average daily volume of 85,538 shares, the days-to-cover ratio is currently 0.7 days.

Caring Brands Price Performance

Shares of CABR traded up $0.06 during mid-day trading on Friday, hitting $1.21. The company’s stock had a trading volume of 37,154 shares, compared to its average volume of 80,184. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.66 and a quick ratio of 5.62. The company has a 50-day moving average of $1.12. Caring Brands has a fifty-two week low of $0.71 and a fifty-two week high of $5.35. The company has a market cap of $11.03 million and a PE ratio of -1.90.

Caring Brands (NASDAQ:CABR) last issued its earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC acquired a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned 0.25% of Caring Brands at the end of the most recent quarter.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.